Home
Drugs
Targets
Pathways
Ontologies
Cyp450s
Adv.search
Help/FAQ

Drug-Target Interaction

Drug

show drug details
PubChem ID:2049
Structure:
Synonyms:
146535-11-7
6,7-dimethoxy-2-phenylquinoxaline
6,7-Dimethoxy-2-phenylquinozaline
6,7-Dimethoxy-3-phenylquinoxaline
AC1L1CT0
AC1Q4WDE
AG 1296
AG-1296
AG1296
AR-1H0393
Bio2_000142
Bio2_000622
BiomolKI2_000061
BiomolKI_000055
BMK1-F7
BRD-K76064317-001-03-2
BRD-K76064317-001-04-0
BSPBio_001422
C106250
CCG-100659
CHEBI:209185
CHEMBL71191
HMS1361H04
HMS1791H04
HMS1989H04
HMS3229M21
IDI1_033892
IN1031
KBio2_000142
KBio2_002710
KBio2_005278
KBio3_000283
KBio3_000284
KBioGR_000142
KBioSS_000142
MolPort-009-019-347
NCGC00163386-01
NCGC00163386-02
NCGC00163386-03
Quinozaline, 6,7-dimethoxy-2-phenyl-
SR-03000001061
SR-03000001061-1
Tyrphostin AG 1296
tyrphostin-AG1296
ZINC00008082

Target

show target details
Uniprot ID:Q9Y354_HUMAN
Synonyms:
Matrix metalloproteinase 9
EC-Numbers:3.4.24.35
Organism:Homo sapiens
Human
PDB IDs:-

Binding Affinities:

Ki: Kd:Ic 50:Ec50/Ic50:
----

References:

18571505
Inhibiting the platelet derived growth factor receptor increases signs of retinoic acid syndrome in myeloid differentiated HL-60 cells.. Gudrun Reiterer; Rodica P Bunaciu; James L Smith; Andrew Yen (2008) FEBS letters display abstract
PDGFR inhibitors are successfully used in a number of cancer treatments. The standard treatment for acute promyelocytic leukemia (APL) involves differentiation therapy with retinoic acid (RA). However, the relapse rates are significant. In the present work we evaluated the effects of RA therapy in the presence of PDGFR inhibitor, AG1296. Adding AG1296 with RA increased secretion of TNF-alpha, IL-8, and MMP-9 expression. This treatment induced higher levels of ICAM-1 endothelial cell expression, and increased cellular mobility. Inhibiting PDGFR enhanced RA-induced expression of integrin. Integrin ligand increased differentiation markers CD11b, inducible oxidative metabolism and PDGFR-beta phosphorylation. While the neutrophil-endothelial cell interactions are strengthened by the combined treatment, the endothelium-substratum interactions are weakened, a situation common in RAS.